Yesterday was a great day for our life sciences portfolio. In reality, every day is a great day when you are working with amazing scientists and innovators to improve and save lives. But yesterday a number of our companies were recognized for their incredible efforts to change the world for the better.
In the morning, two of our portfolio companies were named to the Fierce Biotech’s 2014 Fierce 15 list. Navitor Pharmaceuticals, which is developing drugs for metabolic and inflammatory disease based on nutrient signaling (we recently highlighted here) and Editas Medicine which is doing groundbreaking gene editing work, were both included among some very good company. Polaris-backed companies have always had a strong showing on this list – appearing no less than 15 times. We are so proud of our teams that are being recognized — and our partners who support them — Alan Crane and Kevin Bitterman.
In the afternoon, T2 Biosystems announced that they had received FDA approval to market T2 Candida and T2 Dx for the detection of Sepsis Causing Pathogens. This is fantastic news for the company which went public in August of this year – but it is even more meaningful for patients who require this vital test which for the first time will now take just three to five hours for detection. Blood culture which is the current standard of care can take up to 6 days or more to provide results.
Here’s to carrying this momentum into the rest of the week!